For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Scientific Program

FP268

3927MW

Dr.Ghizala begum c
Membership No Author Name Email Mobile
3927MW Dr.Ghizala begum c ghizalabegummbbs@gmail.com 8867438004
Community Ophthalmology

A Race for Relief: Alcaftadine Versus Bepotastine in VKC

ABSTARCT
Background & Objectives: Vernal keratoconjunctivitis (VKC) is a recurrent allergic ocular surface disorder affecting children and adolescents. This study compared the efficacy and safety of alcaftadine 0.25% and bepotastine 1.5% in mild to moderate VKC.
Methods: In this prospective comparative study, 112 patients were allocated to alcaftadine (n=56) or bepotastine (n=56). TOSS, hyperemia, and papillae were assessed at baseline and Weeks 1, 3, 5, and 8.
Results: Both groups showed significant improvement over time (p<0.001). At Week 3, bepotastine produced significantly lower TOSS (0.59±0.50 vs 1.43±0.50), hyperemia (0.57±0.50 vs 1.27±0.45), and papillae scores (0.73±0.45 vs 1.41±0.50) than alcaftadine (all p<0.001). Outcomes were comparable by Week 5 and remained so at Week 8. No serious adverse events occurred.
Conclusion: Both drugs were safe and effective, but bepotastine provided faster early clinical improvement.

Membership No Author Name Email Mobile
1981 Dr.Abhishek Kulkarni abhi.5555@gmail.com 8050155550
1884 Dr.Sangeeta Vivek Patil sangeetavivek.patil@gmail.com 9535887750
2256 Dr.Sana Hussaini sanamustafahussaini@gmail.com 9739786909